Advanced Solid Malignancies
57
6
10
36
Key Insights
Highlights
Success Rate
84% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
12.3%
7 terminated out of 57 trials
83.7%
-2.8% vs benchmark
2%
1 trials in Phase 3/4
22%
8 of 36 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 36 completed trials
Clinical Trials (57)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib
Phase I Study of the Safety, Tolerability, and Efficacy of an Engineered Mitochondrial Vaccine in Advanced Solid Tumors
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC2027 in Patients With Advanced Solid Malignancies
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects with Advanced Solid Tumors
An Open-Label Phase 1 Study of Ceralasertib in Japanese Patients With Advanced Solid Malignancies
Drug-drug Interaction Study With AZD5305 and Itraconazole in Patients With Advanced Solid Malignancies
Evaluate Safety, Tolerability, PK, Preliminary Clinical Activity of OB318 in Patients With Advanced Solid Malignancies
A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies
A Phase I Open-label Study for Subjects With Advanced Malignancies